The US FDA has granted Breakthrough Therapy Designation status to Israel’s Teva for its SD-809 (deutetrabenazine) treatment of patients with tardive dyskinesia, a hyperkinetic movement disorder affecting about 500,000 people in the USA.

http://www.tevapharm.com/news/teva_announces_breakthrough_therapy_designation_for_sd_809_granted_by_fda_for_the_treatment_of_tardive_dyskinesia_11_15.aspx